Quality improvement of paediatric care in the Netherlands

Tom W J Schulpen1, Kiki M J Lombarts

  • 1Office for Quality Management, Paediatric Association of the Netherlands, Utrecht, The Netherlands. Schulpen@worldonline.nl

Insights

The Paediatric Association of the Netherlands developed a quality improvement program for pediatric care, featuring peer site visits, education, guidelines, and patient safety. This program enhances quality and could be a model for other nations.

Area of Science:

  • Pediatric Healthcare Quality Improvement
  • Medical Education and Professional Development
  • Patient Safety in Hospitals

Background:

  • The Dutch government's national program established a framework for quality improvement.
  • The Paediatric Association of the Netherlands (PAN) developed a comprehensive quality improvement program.
  • Healthcare quality is increasingly scrutinized and regulated.

Purpose of the Study:

  • To describe the development and structure of the PAN's quality improvement program.
  • To highlight the key components and reception of the program.
  • To assess the program's impact on pediatric care quality.

Main Methods:

  • The program is built on four pillars: peer site visits (visitatie), continuous medical education, evidence-based clinical guideline development, and patient safety with complication registration.
  • Peer site visits are central to assessing quality improvement in hospital-based pediatric care.
  • A self-assessment approach and confidential nature of visits were employed.

Main Results:

  • Peer site visits are a key component in evaluating quality improvement in pediatric hospital care.
  • The self-assessment method and the confidential nature of peer visits were positively received by specialists.
  • The integration of quality criteria into the mandatory 5-year medical specialist recertification process has significantly improved focus on quality.

Conclusions:

  • The PAN's quality improvement program, with its emphasis on peer review and continuous development, has positively impacted pediatric care.
  • The program's structure and successful implementation, particularly the peer review component, offer a potential model for other countries.
  • Mandatory inclusion of quality criteria in recertification processes can effectively drive quality improvement initiatives in healthcare.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Standards of Care II01:19

Standards of Care II

Nurses bear specific legal responsibilities under several federal statutes, including:
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...